A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

NCT06947499 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1186

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Pertussis
Hepatitis B
Poliomyelitis
Haemophilus Influenzae Type b

Interventions

BIOLOGICAL: LBVD
BIOLOGICAL: Pentavalent vaccine and Inactivated Polio vaccine

Sponsor

LG Chem